Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hereditary Angioedema Market: By Product, By Drug Class By Route of Administration and Geography
Hereditary angioedema market size was valued at US$ 2,737.3 million in 2023 and is projected to grow at a CAGR of 37.4% from 2024-2030. Hereditary Angioedema (HAE) is a hereditary disease. There is a 50% probability that a parent with HAE will pass it on to their offspring. As a result of a spontaneous gene mutation, HAE can also develop in people with no family history. HAE is managed by acute attack management, short-term prophylaxis, and long-term prophylaxis. The Kalbitor, Ruconest, Icatibant, Firazyr and Berinert are using for acute attack management. The Orladeyo, Cinryze, Haegarda, and Takhzyro drugs are using for short-term and long term prophylaxis treatment. The diversity of HAE's phenotype makes diagnosis challenging. Initial misdiagnoses happen frequently.
For instance, HAE-related edoema can be mistaken for an allergic reaction. It is possible to misinterpret gastrointestinal symptoms for the gastrointestinal disease alone. Due to its rarity and significant symptom overlap with other conditions, HAE is rarely detected early, usually disregarded, and misdiagnosed. The right diagnosis typically takes a patient more than 10 years after the onset of symptoms. Even though the illness is uncommon, it is dangerous.
STAR 0125 for Hereditary Angioedema Therapeutics and Market Value (US$ Million), 2027 -2030 in USA
KalVista (Sebetralstat – On Demand & KVD-824 - Prophylaxis) for Hereditary Angioedema Therapeutics and Market Value (US$ Million), 2024 -2029 in USA
Study Period
2024-2030Base Year
2023CAGR
37.4%Largest Market
Asia PacificFastest Growing Market
North America
Around 14 drug molecules are in various clinical developmental stages, the majority of the molecules are in phase-I & II clinical stages. And few drug molecules such as KVD-900, CSL 312; Factor XIIa antagonist monoclonal antibody, Donidalorsen, are in Phase III clinical developmental stages.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 2,737.3 million |
Market CAGR |
37.4% |
By Product Type |
|
By Drug Class |
|
By Route of Administration |
|
By Region |
|
Download Free Sample Report
The global hereditary angioedema market size was valued at US$ 2,737.3 million in 2023 and is projected to grow at a CAGR of 37.4% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The hereditary angioedema treatment market key players are CSL Behring (Garadacimab) Takeda Pharming Biocryst Pharmaceutics (BCX-4161) Pharvaris (PHA 121) Ionis Pharmaceuticals (Donidalorsen)
1.Executive Summary |
2.Global Hereditary Angioedema Market Introduction |
2.1.Global Hereditary Angioedema Market - Taxonomy |
2.2.Global Hereditary Angioedema Market - Definitions |
2.2.1. By Product Type |
2.2.2. By Drug Class |
2.2.3. By Route of Administration |
2.2.4. By Region |
3.Global Hereditary Angioedema Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Hereditary Angioedema Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Hereditary Angioedema Market By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Kalbitor |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Ruconest |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Icatibant |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Firazyre |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Berinert |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Orladeyo |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Cinryze |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Haegarda |
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.9. Takhzyro |
5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
5.10. Others |
5.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.10.3. Market Opportunity Analysis |
6.Global Hereditary Angioedema Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. C1-esterase inhibitor |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Bradykinin B2 receptor antagonist |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Kallikrein inhibitor |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Hereditary Angioedema Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Intravenous |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Subcutaneous |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Oral |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Hereditary Angioedema Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Kalbitor |
9.1.2.Ruconest |
9.1.3.Icatibant |
9.1.4.Firazyre |
9.1.5.Berinert |
9.1.6.Orladeyo |
9.1.7.Cinryze |
9.1.8.Haegarda |
9.1.9.Takhzyro |
9.1.10.Others |
9.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.C1-esterase inhibitor |
9.2.2.Bradykinin B2 receptor antagonist |
9.2.3.Kallikrein inhibitor |
9.2.4.Others |
9.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Intravenous |
9.3.2.Subcutaneous |
9.3.3.Oral |
9.3.4.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Kalbitor |
10.1.2.Ruconest |
10.1.3.Icatibant |
10.1.4.Firazyre |
10.1.5.Berinert |
10.1.6.Orladeyo |
10.1.7.Cinryze |
10.1.8.Haegarda |
10.1.9.Takhzyro |
10.1.10.Others |
10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.C1-esterase inhibitor |
10.2.2.Bradykinin B2 receptor antagonist |
10.2.3.Kallikrein inhibitor |
10.2.4.Others |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Intravenous |
10.3.2.Subcutaneous |
10.3.3.Oral |
10.3.4.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Kalbitor |
11.1.2.Ruconest |
11.1.3.Icatibant |
11.1.4.Firazyre |
11.1.5.Berinert |
11.1.6.Orladeyo |
11.1.7.Cinryze |
11.1.8.Haegarda |
11.1.9.Takhzyro |
11.1.10.Others |
11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.C1-esterase inhibitor |
11.2.2.Bradykinin B2 receptor antagonist |
11.2.3.Kallikrein inhibitor |
11.2.4.Others |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Intravenous |
11.3.2.Subcutaneous |
11.3.3.Oral |
11.3.4.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Kalbitor |
12.1.2.Ruconest |
12.1.3.Icatibant |
12.1.4.Firazyre |
12.1.5.Berinert |
12.1.6.Orladeyo |
12.1.7.Cinryze |
12.1.8.Haegarda |
12.1.9.Takhzyro |
12.1.10.Others |
12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.C1-esterase inhibitor |
12.2.2.Bradykinin B2 receptor antagonist |
12.2.3.Kallikrein inhibitor |
12.2.4.Others |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Intravenous |
12.3.2.Subcutaneous |
12.3.3.Oral |
12.3.4.Others |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Kalbitor |
13.1.2.Ruconest |
13.1.3.Icatibant |
13.1.4.Firazyre |
13.1.5.Berinert |
13.1.6.Orladeyo |
13.1.7.Cinryze |
13.1.8.Haegarda |
13.1.9.Takhzyro |
13.1.10.Others |
13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.C1-esterase inhibitor |
13.2.2.Bradykinin B2 receptor antagonist |
13.2.3.Kallikrein inhibitor |
13.2.4.Others |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Intravenous |
13.3.2.Subcutaneous |
13.3.3.Oral |
13.3.4.Others |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.CSL Behring (Garadacimab) |
14.2.2.Takeda |
14.2.3.Pharming |
14.2.4.Biocryst Pharmaceutics (BCX-4161) |
14.2.5.Pharvaris (PHA 121) |
14.2.6.Ionis Pharmaceuticals (Donidalorsen) |
14.2.7.Attune Pharmaceuticals (ATN-249) |
14.2.8.Arrowhead Pharmaceuticals (ARO-F12) |
14.2.9.Adverum Biotechnologies |
14.2.10.KalVista Pharmaceuticals (KVD-900, KVD 824 & Factor XIIa inhibitors) |
14.2.11.Centogene |
14.2.12.Spark Therapeutics (Gene Therapy) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players